These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 34445083)
21. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Hua Y; Sahashi K; Hung G; Rigo F; Passini MA; Bennett CF; Krainer AR Genes Dev; 2010 Aug; 24(15):1634-44. PubMed ID: 20624852 [TBL] [Abstract][Full Text] [Related]
23. The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy. Singh RN; Ottesen EW; Singh NN Neurosci Insights; 2020; 15():2633105520973985. PubMed ID: 33283185 [TBL] [Abstract][Full Text] [Related]
24. Dual masking of specific negative splicing regulatory elements resulted in maximal exon 7 inclusion of SMN2 gene. Pao PW; Wee KB; Yee WC; Pramono ZA Mol Ther; 2014 Apr; 22(4):854-61. PubMed ID: 24317636 [TBL] [Abstract][Full Text] [Related]
25. Rescue of gene-expression changes in an induced mouse model of spinal muscular atrophy by an antisense oligonucleotide that promotes inclusion of SMN2 exon 7. Staropoli JF; Li H; Chun SJ; Allaire N; Cullen P; Thai A; Fleet CM; Hua Y; Bennett CF; Krainer AR; Kerr D; McCampbell A; Rigo F; Carulli JP Genomics; 2015 Apr; 105(4):220-8. PubMed ID: 25645699 [TBL] [Abstract][Full Text] [Related]
34. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice. Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718 [TBL] [Abstract][Full Text] [Related]
35. LNA/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts. Touznik A; Maruyama R; Hosoki K; Echigoya Y; Yokota T Sci Rep; 2017 Jun; 7(1):3672. PubMed ID: 28623256 [TBL] [Abstract][Full Text] [Related]
36. Splicing-Correcting Therapy for SMA. Wan L; Dreyfuss G Cell; 2017 Jun; 170(1):5. PubMed ID: 28666123 [TBL] [Abstract][Full Text] [Related]
37. Synergistic Effect of an Antisense Oligonucleotide and Small Molecule on Splicing Correction of the Spinal Muscular Atrophy Gene. Ottesen EW; Singh RN Neurosci Insights; 2024; 19():26331055241233596. PubMed ID: 38379891 [TBL] [Abstract][Full Text] [Related]
38. A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice. Zhou H; Janghra N; Mitrpant C; Dickinson RL; Anthony K; Price L; Eperon IC; Wilton SD; Morgan J; Muntoni F Hum Gene Ther; 2013 Mar; 24(3):331-42. PubMed ID: 23339722 [TBL] [Abstract][Full Text] [Related]
39. Gender-Specific Amelioration of SMA Phenotype upon Disruption of a Deep Intronic Structure by an Oligonucleotide. Howell MD; Ottesen EW; Singh NN; Anderson RL; Singh RN Mol Ther; 2017 Jun; 25(6):1328-1341. PubMed ID: 28412171 [TBL] [Abstract][Full Text] [Related]
40. Nusinersen ameliorates motor function and prevents motoneuron Cajal body disassembly and abnormal poly(A) RNA distribution in a SMA mouse model. Berciano MT; Puente-Bedia A; Medina-Samamé A; Rodríguez-Rey JC; Calderó J; Lafarga M; Tapia O Sci Rep; 2020 Jul; 10(1):10738. PubMed ID: 32612161 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]